News Wire

The FDA has approved Gamifant (emapalumab-lzsg, Sobi and NovImmune SA), an interferon gamma (IFNγ) blocking antibody for the treatment of pediatric and adult patients who have primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or an intolerance to conventional therapy.

The FDA has expanded the use of Promacta (eltrombopag, Novartis) to include first-line treatment for patients from the age of two years who have severe aplastic anemia (SAA). Eltrombopag will be used in combination with standard immunosuppressive therapy (IST) and is the first new treatment in decades for newly-diagnosed SAA patients in the U.S.

Drug products intended to be sterile that are produced and distributed by Pharm D Solutions LLC, Texas, should not be used. Administering a non-sterile drug product that is intended to be sterile could result in serious and potentially life-threatening infections or death.

Patients undergoing treatment for or management of pain are often given pain medications in the spinal fluid (intrathecal administration) that are not FDA-approved for use with their implanted pump. While some patients may experience relief from such medicines, using them could cause additional risks including dosing errors, pump failures, and other safety concerns.

There is no cure and no vaccine, and that phrase is making more people nervous, especially parents.

The expansion of scope of practice for nurse practitioners (NPs) and physician assistants (PAs) in some states, changes in the way health plan benefit packages are structured, and a shortage of primary care physicians (PCPs) helped to drive more visits to NPs and PAs, and fewer to PCPs, accor

Hospitals have always advertised their services to consumers. But what the industry spends on such advertising rose 41% between 2011 and 2015, according to data by Advertising Age and as reported by Kaiser Health News (KHN) this morning.

Value-based care continues to make inroads, or at least headlines.

This one is getting people nervous, not only because of the epidemiology but also because of who’s most affected. The CDC is trying to find out exactly what’s afflicted about 160 people with a polio-like virus.

The FDA has approved revefenacin (Yupelri, Theravance Biopharma, Dublin, Ireland and Mylan, Canonsburg, Pennsylvania) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). A long-acting muscarinic antagonist (LAMA), Yupelri is the first and only once-daily, nebulized bronchodilator approved for COPD in the U.S.

MaxQ AI (formerly MedyMatch, Tel Aviv, Israel) has received FDA 510(k) marketing clearance for Accipio, an artificial intelligence software that can rapidly detect brain bleeds in computerized tomography (CT) scans.

A new study indicates that empagliflozin, a diabetes medication, can improve cardiac structure in people with type-2 diabetes (T2D) who also have heart disease. Results from EMPA-HEART were presented at a late-breaker session at the American Heart Association on November 11.

A study published November 12 in Cancer Cell reports that the experimental drug GSK547 (GlaxoSmithKline, Brentford, UK) may prove effective against a deadly form of pancreatic cancer when used together with other immune-boosting therapies.

More states want to know exactly how PBMs make from pharmaceuticals purchased by Medicaid.

The effort to repeal and/or replace the ACA got pushed to the margins of political discourse Tuesday.

Pages